Zenas BioPharma, Inc.
Company Stats
- Market Cap
- $1.8B
- as of Sep 30, 2026
- Shares Outstanding
- 65.2M
- Free Float
- 42.6%
Income Statement
- Revenue
- $10.0M
- Operating Income
- -$383.1M
- Net Income
- -$377.7M
- EBITDA
- -$383.0M
- FCF Margin, 3Y Avg
- -1393.6%
- FCF Margin, Worst Year
- -2396.1%
Cash Flow
- Free Cash Flow
- -$172.4M
- FCF Yield
- -9.8%
- Owner FCF Yield
- -11.3%
Balance Sheet
- Cash & Equivalents
- $110.6M
Returns & Capital
- SBC, 3Y Avg
- $13.6M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $10.0M | -$172.4M | -1723.5% |
| FY2024 | $5.0M | -$119.8M | -2396.1% |
| FY2023 | $50.0M | -$30.5M | -61.1% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 15, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges